GlassScriptPhysician profile
Paul Herman
NPI 1720027584
$505.04
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $143 · 2021: $79.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $96.76 | 2019 | |
| Cranial Technologies, INC | $84.53 | 2019-2021 | |
| Pfizer INC. | $76.36 | 2019-2021 | |
| Neos Therapeutics, LP | $64.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.21 | 2020 | |
| Shire North American Group INC | $28.58 | 2019 | |
| Merck Sharp & Dohme LLC | $26.28 | 2019-2020 | |
| Sanofi Pasteur INC. | $24.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.82 | 2019 | |
| Tris Pharma INC | $15.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.